sirolimus
Phase 2- Indications
- Vascular access stenosis, Hemodialysis vascular access
Company intelligence / Profile preview
Vascular Therapies
New Jersey, United Statesvasculartx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Sirogen™, a bioabsorbable sirolimus-eluting implant, has completed patient enrollment in multiple Phase III trials aimed at improving vascular access outcomes for hemodialysis patients by reducing stenosis and increasing the usability and longevity of AV fistulas
- Therapeutic areas
- CardiovascularNephrology
- Modalities
- Drug-device combination (bioresorbable collagen-based implant delivering sirolimus)
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Vascular Therapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vascular Therapies.